UY32882A - (heteroarilmetil) tiohidantoínas sustituidas - Google Patents

(heteroarilmetil) tiohidantoínas sustituidas

Info

Publication number
UY32882A
UY32882A UY0001032882A UY32882A UY32882A UY 32882 A UY32882 A UY 32882A UY 0001032882 A UY0001032882 A UY 0001032882A UY 32882 A UY32882 A UY 32882A UY 32882 A UY32882 A UY 32882A
Authority
UY
Uruguay
Prior art keywords
substituted
thiohidantoins
heteroarilmetil
preparation
treatment
Prior art date
Application number
UY0001032882A
Other languages
English (en)
Spanish (es)
Inventor
Dr Ulrich Luecking
Dr Arwed Cleve
Dr Bernard Haendler
Dr Hortensia Faus
Dr Silke Koehr
Dr Horst Irlbacher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32882A publication Critical patent/UY32882A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UY0001032882A 2009-09-11 2010-09-08 (heteroarilmetil) tiohidantoínas sustituidas UY32882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17

Publications (1)

Publication Number Publication Date
UY32882A true UY32882A (es) 2011-04-29

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032882A UY32882A (es) 2009-09-11 2010-09-08 (heteroarilmetil) tiohidantoínas sustituidas

Country Status (28)

Country Link
US (1) US20120251551A1 (OSRAM)
EP (1) EP2475653A1 (OSRAM)
JP (1) JP2013504523A (OSRAM)
KR (1) KR20120065396A (OSRAM)
CN (1) CN102639523A (OSRAM)
AR (1) AR078166A1 (OSRAM)
AU (1) AU2010294588A1 (OSRAM)
BR (1) BR112012005526A2 (OSRAM)
CA (1) CA2773591A1 (OSRAM)
CL (1) CL2012000623A1 (OSRAM)
CO (1) CO6511228A2 (OSRAM)
CR (1) CR20120113A (OSRAM)
CU (1) CU20120042A7 (OSRAM)
DO (1) DOP2012000063A (OSRAM)
EA (1) EA201200473A1 (OSRAM)
EC (1) ECSP12011716A (OSRAM)
IL (1) IL218390A0 (OSRAM)
IN (1) IN2012DN02081A (OSRAM)
MA (1) MA33566B1 (OSRAM)
MX (1) MX2012002977A (OSRAM)
NZ (1) NZ598643A (OSRAM)
PE (1) PE20121180A1 (OSRAM)
PH (1) PH12012500497A1 (OSRAM)
SG (1) SG178919A1 (OSRAM)
TN (1) TN2012000108A1 (OSRAM)
TW (1) TW201111378A (OSRAM)
UY (1) UY32882A (OSRAM)
WO (1) WO2011029537A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164776A (en) 2010-02-17 2018-01-30 Takeda Pharmaceuticals Co Heterocyclic compound
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013265194B2 (en) 2012-05-25 2018-01-04 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
RS63939B1 (sr) * 2013-12-11 2023-02-28 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
WO2015169677A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
WO2017060167A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018177899A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CN110770210A (zh) 2017-05-18 2020-02-07 Pi工业有限公司 新颖的脒化合物
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
WO2020209933A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
AU754529B2 (en) 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
BR0309188A (pt) 2002-04-12 2005-02-09 Pfizer Compostos pirazolo como agentes antiinflamatórios e analgésicos
US20060247286A1 (en) 2003-07-02 2006-11-02 Milton Hammond Oxazolidinone antibiotics and derivatives thereof
DE602004020364D1 (de) 2003-09-30 2009-05-14 Janssen Pharmaceutica Nv Benzoimidazolverbindungen
AU2004303602C1 (en) 2003-12-23 2009-05-28 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
JP4912148B2 (ja) 2004-08-03 2012-04-11 中外製薬株式会社 新規イミダゾリジン誘導体
JP4989227B2 (ja) * 2004-09-09 2012-08-01 中外製薬株式会社 新規イミダゾリジン誘導体およびその用途
RU2389721C2 (ru) 2004-12-03 2010-05-20 Ф.Хоффманн-Ля Рош Аг 3-замещенные производные пиридина в качестве антагонистов гистаминовых н3 рецепторов
DK2444085T3 (en) * 2005-05-13 2015-04-27 Univ California Diarylhydantoinforbindelser as androgenreceptorantagonister for treating cancer
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
CA2703635C (en) 2007-10-26 2017-06-27 Michael E. Jung Diarylhydantoin compounds as androgen receptor modulators
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
IN2012DN02081A (OSRAM) 2015-08-21
EP2475653A1 (en) 2012-07-18
EA201200473A1 (ru) 2012-10-30
SG178919A1 (en) 2012-04-27
US20120251551A1 (en) 2012-10-04
CA2773591A1 (en) 2011-03-17
PH12012500497A1 (en) 2012-10-22
CL2012000623A1 (es) 2012-09-14
CU20120042A7 (es) 2012-06-21
PE20121180A1 (es) 2012-08-24
MX2012002977A (es) 2012-04-30
CR20120113A (es) 2012-05-02
IL218390A0 (en) 2012-04-30
TN2012000108A1 (en) 2013-09-19
MA33566B1 (fr) 2012-09-01
WO2011029537A1 (en) 2011-03-17
KR20120065396A (ko) 2012-06-20
CO6511228A2 (es) 2012-08-31
NZ598643A (en) 2013-10-25
BR112012005526A2 (pt) 2016-04-26
CN102639523A (zh) 2012-08-15
DOP2012000063A (es) 2012-05-15
TW201111378A (en) 2011-04-01
AR078166A1 (es) 2011-10-19
JP2013504523A (ja) 2013-02-07
ECSP12011716A (es) 2012-04-30
AU2010294588A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
ECSP10010216A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
SMT201400148B (it) Inibitori di jak2 e loro uso per il trattamento del cancro e di malattie mieloproliferative
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EA201171367A1 (ru) Винилиндазолильные соединения
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127